Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Low body mass index and latent tuberculous infection: a systematic review and meta-analysis.

Saag LA, LaValley MP, Hochberg NS, Cegielski JP, Pleskunas JA, Linas BP, Horsburgh CR.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):358-365. doi: 10.5588/ijtld.17.0558.

PMID:
29562981
2.

Factors Associated With All-Cause Mortality Among Patients With Multidrug-Resistant Tuberculosis-United States, 1993-2013.

Salinas JL, Armstrong LR, Silk BJ, Haddad MB, Cegielski JP.

Clin Infect Dis. 2017 Nov 13;65(11):1924-1926. doi: 10.1093/cid/cix667.

PMID:
29020169
3.

Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Cavanaugh JS, Jou R, Wu MH, Dalton T, Kurbatova E, Ershova J, Cegielski JP; Global PETTS Investigators.

J Antimicrob Chemother. 2017 Jun 1;72(6):1678-1687. doi: 10.1093/jac/dkx022.

PMID:
28333192
4.

Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa.

Kvasnovsky CL, Cegielski JP, van der Walt ML.

Emerg Infect Dis. 2016 Sep;22(9). doi: 10.3201/eid2209.160084.

5.

Associations Between Vitamin D Level and Hospitalizations With and Without an Infection in a National Cohort of Medicare Beneficiaries.

Kempker JA, Magee MJ, Cegielski JP, Martin GS.

Am J Epidemiol. 2016 May 15;183(10):920-9. doi: 10.1093/aje/kwv306. Epub 2016 Apr 18.

6.

Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS.

BMC Infect Dis. 2016 Feb 1;16:45. doi: 10.1186/s12879-016-1375-8.

7.

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.

Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.

PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec.

8.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

9.

Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia.

Ershova JV, Volchenkov GV, Kaminski DA, Somova TR, Kuznetsova TA, Kaunetis NV, Cegielski JP, Kurbatova EV.

Emerg Infect Dis. 2015 Nov;21(11):2048-51. doi: 10.3201/eid2111.150813.

10.

Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.

Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, Maryandyshev AO, Shemyakin IG, Kurbatova E, Cegielski JP.

Emerg Infect Dis. 2015 Jun;21(6):1002-11. doi: 10.3201/eid2106.141907.

11.

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.

Kurbatova EV, Dalton T, Ershova J, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Cegielski JP.

Emerg Infect Dis. 2015 Jun;21(6):977-83. doi: 10.3201/eid2106.141329.

12.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

13.

Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.

Cegielski JP, Chen MP, Tupasi TE, Leimane V, Volchenkov GV; Global Preserving Effective TB Treatment Study Investigators.

Clin Infect Dis. 2015 Mar 15;60(6):971-3. doi: 10.1093/cid/ciu1150. Epub 2014 Dec 19. No abstract available.

14.

Annual risk of tuberculous infection measured using serial skin testing, Orel Oblast, Russia, 1991-2005.

Yuen CM, Krapivina TM, Kazennyy BY, Kiryanova EV, Aksenova VA, Gordina A, Finlay AM, Cegielski JP.

Int J Tuberc Lung Dis. 2015 Jan;19(1):39-43. doi: 10.5588/ijtld.14.0445.

PMID:
25519788
15.

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S; Global Preserving Effective TB Treatment Study (PETTS) Investigators.

Clin Infect Dis. 2014 Oct 15;59(8):1049-63. doi: 10.1093/cid/ciu572. Epub 2014 Jul 23.

16.

Eliminating tuberculosis one neighborhood at a time.

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP Jr, Wallace C.

Am J Public Health. 2014 Apr;104 Suppl 2:S214-33. doi: 10.2105/AJPH.2012.300781r.

17.

Mortality among tuberculosis patients with acquired resistance to second-line antituberculosis drugs--United States, 1993-2008.

Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP.

Clin Infect Dis. 2014 Aug 15;59(4):465-72. doi: 10.1093/cid/ciu372. Epub 2014 May 20.

18.

Association between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistance.

Yuen CM, Kurbatova EV, Click ES, Cavanaugh JS, Cegielski JP.

PLoS One. 2013 Dec 23;8(12):e83006. doi: 10.1371/journal.pone.0083006. eCollection 2013.

19.

[Eliminating tuberculosis one neighborhood at a time].

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP, Wallace C.

Rev Panam Salud Publica. 2013 Oct;34(4):284-94. Spanish.

20.

Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.

Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP.

Clin Infect Dis. 2013 Oct;57(8):1081-93. doi: 10.1093/cid/cit452. Epub 2013 Jul 9.

Supplemental Content

Loading ...
Support Center